Torrent Pharmaceuticals Ltd

TORNTPHARM

Watchlist

AI Mode

‌

Market Cap

₹ 1,27,957 Cr

P/E

59.06

Turned 1 L into 2.72 L in last 5 Years

‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

OVERVALUED

Growth

STABLE

Profitability

HIGH MARGIN

Technicals

Bullish

Risk

LOW RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Torrent Pharmaceuticals Limited is a key player in the Indian pharma sector, specializing in chronic and sub-chronic therapies like Cardiovascular and Central Nervous System.

The company recorded substantial growth with revenues of Rs. 3,302 crores and an operating EBITDA margin of 32.8% for Q2 FY'26.

India business growth was driven by cardiac and gastro therapies, while Brazil registered 21% growth, underscoring its strong international markets presence.

The US segment witnessed a 26% growth, benefitting from new launches and increased purchase volume of existing contracts.

Significant field force expansion and strategic product launches in India and Brazil suggest a focused approach on market penetration and growth.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

1,27,957 Cr

Volatility

Low Risk

P/E Ratio

59.1

Industry P/E

43.8

PEG Ratio

3.3

P/B Ratio

15.1

52W High

3,880.55

52W Low

2,891.45

Sales CAGR

7.35%

12.82%

9.44%

10Y

6.62%

Profit CAGR

15.39%

23.95%

15.00%

10Y

0.89%

ROE

TTM

25.33%

23.31%

21.09%

10Y

21.39%

ROCE

TTM

27.37%

26.50%

23.60%

1Y Price Target

4073.01 ▲ 8.58%

Q3 EPS Estimate

Q3 Revenue Estimate

Unlock Premium Features

Price, EPS and Revenue Projections

Strong SellSellHoldBuyStrong Buy

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

updated on

Dec 03, 2025

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
TORNTPHARM	3791.95	1,27,957 Cr	59.06	15.14	0.16	25.33	27.37	13.79
AJANTPHARM	2638.15	32,971 Cr	33.86	7.64	1.06	22.56	27.85	17.17
GLAND	1669.90	27,513 Cr	34.81	2.88	1.08	8.27	12.46	6.70
ERIS	1588.20	21,607 Cr	51.97	6.99	0.46	13.45	14.38	6.27
SAILIFE	909.85	19,138 Cr	66.80	8.43	0.00	12.62	16.34	8.60
CAPLIPOINT	1957.00	14,864 Cr	25.24	4.70	0.31	18.64	23.29	17.02
RUBICON	634.55	10,481 Cr	78.34	10.03	0.00	41.49	34.93	8.82

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	2,591	2,660	2,732	2,745	2,859	2,889	2,809	2,959	3,178	3,302
Expenses	1,800	1,835	1,863	1,862	1,955	1,950	1,895	1,995	2,146	2,219
Operating Profit	791	825	869	883	904	939	914	964	1,032	1,083
OPM %	30.53	31.02	31.81	32.17	31.62	32.50	32.54	32.58	32.47	32.80
Other Income	34	26	55	31	24	-16	33	-42	-37	-40
Interest	103	91	80	80	75	64	57	56	56	48
Depreciation	191	201	213	203	197	198	199	201	201	204
Profit Before Tax	531	559	631	631	656	661	691	665	738	791
Tax %	28.81	30.95	29.79	28.84	30.34	31.47	27.21	25.11	25.75	25.28
Net Profit	378	386	443	449	457	453	503	498	548	591
EPS in Rs	11.18	11.39	13.10	13.27	13.51	13.37	14.88	14.71	16.19	17.54

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	5,857	5,950	7,673	7,939	8,005	8,508	9,620	10,728	11,516	11,835
Expenses	4,480	4,601	5,690	5,769	5,524	6,077	6,778	7,360	7,795	7,986
Operating Profit	1,377	1,349	1,983	2,170	2,480	2,431	2,842	3,368	3,721	3,849
OPM %	23.52	22.68	25.85	27.34	30.98	28.58	29.54	31.39	32.31	32.52
Other Income	223	299	-300	121	57	-288	45	146	-0.94	-62
Interest	206	308	504	451	353	255	333	354	252	233
Depreciation	307	409	618	654	658	662	707	808	795	799
Profit Before Tax	1,088	931	562	1,187	1,526	1,226	1,847	2,352	2,673	2,755
Tax %	14.20	27.16	22.32	13.64	17.98	36.60	32.59	29.58	28.49	27.33
Net Profit	934	678	436	1,025	1,252	777	1,245	1,656	1,911	2,002
EPS in Rs	27.59	20.04	12.89	30.28	36.99	22.97	36.78	48.94	56.47	63.32
Dividend Payout %	25.38	34.94	65.94	52.85	47.31	209.06	59.80	57.21	56.67	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	85	85	85	85	85	85	85	169	169	169
Reserves	3,409	4,266	4,538	4,640	4,739	5,753	5,868	6,029	6,687	7,421
Borrowings	1,853	2,241	5,737	4,847	4,366	4,874	4,070	5,369	4,022	3,202
Other Liabilities	3,710	3,111	3,884	4,550	4,820	3,363	3,077	3,445	4,182	4,197
Total Liabilities	9,058	9,702	14,243	14,121	14,010	14,075	13,100	15,012	15,061	14,990
Fixed Assets	2,859	3,688	7,855	7,748	7,533	7,065	6,423	8,121	8,138	7,947
CWIP	1,042	519	647	617	712	889	630	765	361	478
Investments	780	804	492	353	2.11	181	226	199	173	156
Other Assets	4,378	4,691	5,249	5,403	5,763	5,939	5,821	5,926	6,389	6,409
Total Assets	9,058	9,702	14,243	14,121	14,010	14,075	13,100	15,012	15,061	14,990

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	2,742	1,009	894	1,798	1,393	2,005	1,803	2,368	3,266	2,585
Cash from Investing Activity	-830	-787	-4,702	-241	199	-449	-197	-2,356	-168	-540
Cash from Financing Activity	-1,435	-193	3,417	-1,314	-1,549	-1,651	-1,781	77	-2,780	-2,298
Net Cash Flow	477	29	-390	242	42	-95	-175	89	319	-253

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	71.25%	71.25%	71.25%	71.25%	71.25%	71.25%	71.25%	71.25%	68.31%	68.31%	68.31%	68.31%
FIIs	12.09%	12.04%	12.84%	13.15%	14.09%	14.14%	14.22%	14.46%	16.17%	16.31%	16.09%	15.92%
DIIs	8.87%	9.00%	8.31%	8.00%	7.21%	7.26%	7.27%	7.08%	8.35%	8.35%	8.66%	9.29%
Public	7.80%	7.71%	7.60%	7.60%	7.45%	7.36%	7.26%	7.21%	7.17%	7.03%	6.94%	6.49%
Total Shareholders	65,237	63,831	61,572	69,612	69,117	71,154	74,765	79,848	85,035	86,005	81,856	78,226

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Nov 29, 2024	Jinesh shah designated person...	Insider - Trust	Acquisition	—	—	9,30,144	—
Oct 30, 2024	Torrent investments private l...	Bulk	Sell	3,103.07	1,542.85 Cr	49,72,020	1.46
Oct 30, 2024	Torrent investments private l...	Bulk	Sell	3,104.40	1,543.51 Cr	49,72,020	1.46
Jan 25, 2024	Bnp paribas arbitrage	Block	Sell	2,507.05	13.93 Cr	55,561	0.01
Jan 25, 2024	Marshallwaceinvestmentstrateg...	Block	Buy	2,507.05	11.86 Cr	47,322	0.01
Jan 25, 2024	Marshall wace investment stra...	Block	Buy	2,507.05	1.09 Cr	4,356	0.00
Jan 25, 2024	Marshall wace investment stra...	Block	Buy	2,507.05	0.97 Cr	3,883	0.00

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Corporate Action

4 days ago

Redemption of Non-Convertible Debentures by Torrent Pharmaceuticals

Torrent Pharmaceuticals has redeemed Rs. 142.84 crores of Non-Convertible Debentures under ISIN: INE685A07082 on December 12, 2025.

Regulatory Filing

6 days ago

ESG Rating Assignment by NSE

NSE Sustainability Ratings assigns an ESG rating of 70 to Torrent Pharmaceuticals, as per SEBI regulations.

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q1 FY23

Investor Presentation

Q4 FY18

Investor Presentation

Q4 FY18

Investor Presentation

Q3 FY18

Investor Presentation

Q3 FY18

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode